Agnes S. Jager

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 385 publications

Survival in the SONIA Trial-Reply.

Survival in the SONIA Trial-Reply.

Journal: JAMA oncology

Published: June 18, 2026

18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial.

18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial.

Journal: JAMA oncology

Published: April 16, 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 25, 2026

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 19, 2026

Characteristics, treatment and survival in de novo and metachronous metastatic breast cancer: a nationwide comparative analysis.

Characteristics, treatment and survival in de novo and metachronous metastatic breast cancer: a nationwide comparative analysis.

Journal: Breast cancer research and treatment

Published: February 13, 2026

Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer.

Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: February 06, 2026

Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial.

Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial.

Journal: BMC cancer

Published: January 14, 2026

Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer.

Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 12, 2026

Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision-Making in Dutch Breast Cancer Patients: A Population-Based Study.

Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision-Making in Dutch Breast Cancer Patients: A Population-Based Study.

Journal: International journal of cancer

Published: December 18, 2025

ASO Visual Abstract: Breast Cancer-Related Lymphedema (BCRL): Comprehensive Characterization of Patients Seeking Microsurgical Treatment.

ASO Visual Abstract: Breast Cancer-Related Lymphedema (BCRL): Comprehensive Characterization of Patients Seeking Microsurgical Treatment.

Journal: Annals of surgical oncology

Published: December 17, 2025

A Worldwide Survey on Pathological Measurement of Residual Breast Cancer After Neoadjuvant Therapy: Different Interpretations of the ypTNM Classification.

A Worldwide Survey on Pathological Measurement of Residual Breast Cancer After Neoadjuvant Therapy: Different Interpretations of the ypTNM Classification.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: December 04, 2025

Machine learning-based identification of high-risk triple-negative breast cancer patients despite pathological complete response after neoadjuvant chemotherapy.

Machine learning-based identification of high-risk triple-negative breast cancer patients despite pathological complete response after neoadjuvant chemotherapy.

Journal: NPJ breast cancer

Published: December 01, 2025

Showing 1-12 of 385

Last Updated: 09/26/2026